pharma · Liver Cirrhosis Due to Hepatitis B Virus
ShuGuang Hospital
ShuGuang Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Liver Cirrhosis Due to Hepatitis B Virus. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 paten
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Entecavir + Placebo
Approved · small molecule · Liver Cirrhosis Due to Hepatitis B Virus
Entecavir + Placebo for Liver Cirrhosis Due to Hepatitis B Virus is a Approved program (small_molecule) at ShuGuang Hospital with 1 ClinicalTrials.gov record(s).
Internal code SGHLC20140818001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ShuGuang Hospital
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Liver Cirrhosis Due to Hepatitis B Virus
- Status
- active
- Trials
- 1